NAPLEX - Parkinson Disease McGraw Hill

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/24

encourage image

There's no tags or description

Looks like no tags are added yet.

25 Terms

1
New cards

NI has been taking carbidopa/levodopa for her Parkinson disease for 6 years. She recently had her dose increased to 50/200 mg po qid, and is now experiencing writhing movements in her trunk and arms. What medication is Food and Drug Administration (FDA)-approved to treat this side effect of carbidopa/levodopa therapy?

A

Gocovri

B

Osmolex

C

Stalevo

D

Symmetrel

A

Gocovri is an extended-release formulation of amantadine that is FDA-approved for the treatment of carbidopa/levodopa-induced dyskinesia.

Answer b is incorrect. While Osmolex is an extended-release formulation of amantadine, it is not FDA-approved for the treatment of dyskinesias.

Answer c in incorrect. Stalevo is a combination of carbidopa/levodopa and entacapone. Adding this drug to NI's current regimen is likely to cause dyskinesias to get worse by increasing the amount of exogenous levodopa administered, as well as inhibiting its breakdown with the use of a catechol-o-methyltransferase (COMT) inhibitor.

Answer d is incorrect. Immediate-release amantadine is not FDA-approved for use as a treatment for dyskinesias.

2
New cards

KJ is a young-onset Parkinson disease patient who was started on therapy approximately 1 month ago. Her husband is on the phone to your clinic concerned about his wife's behavior. He claims that KJ has been shopping online almost continuously over the previous few weeks, and recently went out and purchased a new vehicle without his knowledge. Assuming this is a medication-induced phenomenon, which medication are you most likely to discover when you view KJ's medication profile? Select all that apply.

A

Amantadine

B

Pramipexole

C

Rasagiline

D

Rotigotine

B, D

. Amantadine has not been associated with impulsive behavior.

Answer b is correct. Pramipexole is a dopamine agonist and has been associated with impulsive behaviors including gambling, shopping, and hypersexuality.

Answer c is incorrect. Rasagiline has not been associated with impulsive behavior.

Answer d is correct. Rotigotine is a dopamine agonist and has been associated with impulsive behaviors including gambling, shopping, and hypersexuality.

3
New cards

Which of the monoamine oxidase (MAO) inhibitors has the shortest duration of action on the enzyme?

A

Apomorphine

B

Rasagiline

C

Safinamide

D

Selegiline

C

Rasagiline is an irreversible inhibitor of monoamine oxidase (MAO). It takes approximately 14 days for MAO to reach normal levels after rasagiline discontinuation.

Answer c is correct. Safinamide is a reversible inhibitor of MAO. Its duration of effect on MAO is dependent on its presence in the body.

Answer d is incorrect. Selegiline is an irreversible inhibitor of MAO. It takes approximately 14 days for MAO to reach normal levels after selegiline discontinuation.

4
New cards

SP was diagnosed with Parkinson disease 7 years ago. Originally, she was taking carbidopa/levodopa 25/100 mg po tid, which has since been increased to 50/250 mg po qid. Nonmotor symptoms include constipation and insomnia, and she also has arthritis for which she takes acetaminophen 650 mg po tid. Assuming another medication is to be added at this time, which medication would you suggest avoiding based on her history of present illness?

A

Pramipexole

B

Rasagiline

C

Ropinirole

D

Selegiline

D

. Selegiline has an amphetamine metabolite, and has been associated with an increased incidence of insomnia. Doses should be given no later than early afternoon to help prevent this side effect in a patient for which it is indicated. In a patient with uncontrolled insomnia, the drug is best avoided.

The addition of a dopamine agonist to supplement carbidopa/levodopa is a logical strategy. There appear to be no contraindications or concerns with the addition of this medication to SP's profile.

Answer b is incorrect. Rasagiline is a logical addition to SP's regimen. The drug inhibits monoamine oxidase (MAO)-B thereby increasing the amount of available dopamine in the brain. There appear to be no contraindications or concerns with the addition of this medication to SP's profile.

Answer c is incorrect. The addition of a dopamine agonist to supplement carbidopa/levodopa is a logical strategy. There appear to be no contraindications or concerns with the addition of this medication to SP's profile.

5
New cards

Which medications require adjustment for patients with chronic kidney disease? Select all that apply.

A

Gocovri

B

Neupro

C

Rytary

D

Symmetrel

A, D

The labeling of Gocovri (amantadine extended release [ER]) recommends dose adjustment for patients with a creatinine clearance <60 mL/min.

Answer b is incorrect. No dose adjustment is recommended for patients with renal disease using Neupro (rotigotine) patches.

Answer c is incorrect. No specific dose adjustment recommendations exist for patients using Rytary (carbidopa/levodopa).

Answer d is correct. The labeling of Symmetrel (amantadine immediate release [IR]) recommends dose adjustment for patients with a creatinine clearance <50 mL/min.

6
New cards

GR was recently diagnosed with Parkinson disease. His family practitioner initiated therapy with carbidopa/levodopa 10/100 mg po three times daily. He has been taking the medication with meals, but he is experiencing significant nausea. GR has noticed very little difference in his symptoms. What is the most probable reason GR is experiencing such significant nausea?

A

Carbidopa/levodopa should be taken on an empty stomach.

B

Carbidopa/levodopa should be taken with a meal high in protein.

C

The levodopa component is being converted to dopamine in the periphery.

D

Carbidopa/levodopa always causes nausea.

C

It is true that the drug should be taken on an empty stomach for optimal absorption, but administration with food often helps relieve nausea.

Answer b is incorrect. Amino acids compete with levodopa for transport into the brain. If carbidopa/levodopa is to be taken with food, a low-protein meal is recommended.

Answer c is correct. The minimum daily dose of carbidopa necessary to prevent the peripheral conversion of levodopa to dopamine is 75 to 100 mg. The fact that GR has not noticed improvement in his symptoms supports the notion that levodopa is not crossing the blood-brain barrier to be converted to dopamine.

Answer d is incorrect. Though nausea is a frequent side effect associated with carbidopa/levodopa, it is not inevitable.

7
New cards

MV has been taking carbidopa/levodopa for 6 years. He has begun to develop involuntary movements of his trunk and extremities which include tics and chorea. Which of the following is a true statement about the symptoms MV is experiencing? Select all that apply.

A

The symptoms often appear when the cardinal motor symptoms of Parkinson disease are under good control.

B

Decreasing the dose of levodopa might alleviate the symptoms.

C

They rarely occur early in the disease process.

D

They are more likely to occur with dopamine agonist monotherapy than with carbidopa/levodopa.

A, B

Dyskinesias in the Parkinson's patient frequently occur when disease symptoms are well controlled and dopamine receptors are adequately stimulated. For this reason, the term "peak dose" dyskinesia is often used.

Answer b is correct. Decreasing the levodopa dose may alleviate dyskinesias as a higher total daily levodopa dose appears to be related to onset. However, symptom breakthrough often makes this difficult to achieve.

Answer c is correct. Dyskinesias are associated with levodopa use that has usually been continuous over several years with increasing doses.

Answer d is incorrect. Dopamine agonists are less likely to induce dyskinesias compared to carbidopa/levodopa. For this reason, younger patients are often started on dopamine agonists first to delay carbidopa/levodopa exposure.

8
New cards

One of your long-term Parkinson disease patients, WO, is complaining of hallucinations. She has experienced no recent additions to her medication regimen, or changes in medication doses. Her symptoms include visual hallucinations which are frightening to her, and the decision is made to initiate antipsychotic therapy. Which medication is the best initial choice for the treatment of Parkinson disease associated psychosis?

A

Chlorpromazine

B

Haloperidol

C

Olanzapine

D

Pimavanserin

D

Chlorpromazine, haloperidol, olanzapine is an antidopaminergic antipsychotic and should be avoided in patients with Parkinson disease.

Pimavanserin exerts its activity at serotonergic receptors only. As such, it does not exacerbate symptoms of Parkinson's disease.

9
New cards

CP is taking carbidopa/levodopa 50/200 mg three times per day. She is resistant to the addition of another daily dose of carbidopa/levodopa. Her physician is interested in adding ropinirole to her regimen at the same interval to keep things simple for her. What is the recommendation for dose adjustment with the addition of ropinirole?

A

Increase the carbidopa/levodopa by 1/3.

B

Decrease the carbidopa/levodopa by ¼.

C

Increase the initial ropinirole dose by ¼.

D

No dose adjustments are needed.

B

The addition of a dopamine agonist to carbidopa/levodopa could induce dyskinesias if the carbidopa/levodopa dose is not reduced.

It is recommended that the carbidopa/levodopa dose be adjusted downward by 1/4 to 1/3 to avoid induction of dyskinesias.

10
New cards

NE is a Parkinson disease patient who is nonadherent with her medications because she has difficulty remembering to take all but her morning doses. Which medications are available in formulations that might increase NE's success in taking her medications as prescribed? Select all that apply.

A

Carbidopa/levodopa

B

Pramipexole

C

Rasagiline

D

Rotigotine

B, C, D

Carbidopa/levodopa, despite being available in a controlled-release formulation, must still be dosed multiple times per day, and will necessitate more frequent dosing as the disease progresses.

Answer b is correct. Pramipexole is available in a once-daily extended-release formulation.

Answer c is correct. Rasagiline is a once-daily formulation.

Answer d is correct. Rotigotine is available as a patch that is replaced once daily.

11
New cards

Your Parkinson disease patient HU arrives at your pharmacy wondering what cough and cold products are safe for her to take with her other medications. She currently takes carbidopa/levodopa and rasagiline. Which medication found in over-the-counter options is best avoided by HU?

A

Dextromethorphan

B

Fexofenadine

C

Guaifenesin

D

Phenol

A

. Dextromethorphan is a phenylpiperidine derivative and is believed to be a weak serotonin-reuptake inhibitor. The use of monoamine oxidase (MAO) inhibitors with dextromethorphan is not recommended.

12
New cards

Put the following medications in order according to ability to control motor symptoms of Parkinson disease (bradykinesia, rigidity, tremor) from most efficacious to least efficacious. (Ordered response)

A

Amantadine immediate release (IR)

B

Carbidopa/levodopa

C

Rasagiline

D

Ropinirole

B > D > C > A

Amantadine IRs effects are mild and transient. Its primarily effective for tremor, but does have some limited efficacy for the treatment of rigidity.

Answer c is ranked third. MAO inhibitors help prevent the metabolism of dopamine, but they have no activity at the dopamine receptor. Their efficacy is dependent upon the concentration of dopamine in the brain which decreases with the progression of the disease.

13
New cards

BR has a history of alcohol abuse and is Child-Pugh class B. He has been treated with carbidopa/levodopa five times daily for 6 years, but is wearing off 45 minutes prior to his next scheduled dose. Which medication is contraindicated as an option for prolonging the effects of carbidopa/levodopa in this patient?

A

Entacapone

B

Rasagiline

C

Safinamide

D

Tolcapone

D

The use of tolcapone has been associated with liver toxicity and failure, and its use is contraindicated in patients with pre-existing liver disease.

14
New cards

What is the role of carbidopa in the treatment of Parkinson disease?

A

It inhibits acetylcholine.

B

It inhibits dopa decarboxylase.

C

It inhibits catechol-o-methyltransferase (COMT).

D

It inhibits monoamine oxidase.

B

Carbidopa inhibits dopa decarboxylase to prevent the conversion of levodopa to dopamine in the periphery allowing the drug to cross the blood-brain barrier.

15
New cards

NE is a 74-year-old patient with closed-angle glaucoma, gastroesophageal reflux disease, and hypertension controlled with lisinopril 5 mg po q day. She has just been diagnosed with Parkinson disease and her most prominent symptom is a tremor in her left hand. Which medications are reasonable options for this patient for the initiation of therapy? Select all that apply.

A

Benztropine

B

Carbidopa/levodopa

C

Istradefylline

D

Rasagiline

B, D

Anticholinergic medications are contraindicated in patients with closed-angle glaucoma. In addition, side-effects with anticholinergic medications tend to be more prominent in the elderly.

Answer b is correct. Carbidopa/levodopa replaces dopamine in the brain, and is the most potent of the Parkinson disease medications. NE has no contraindications for its use.

Answer c is incorrect. Istradefylline is an adenosine A2A receptor antagonist that is approved only for use in patients currently taking carbidopa/levodopa.

Answer d is correct. Patients with early stage Parkinson disease will typically make enough endogenous dopamine to see a response with the use of a monoamine oxidase (MAO) inhibitor. Rasagiline is approved for use as monotherapy. HTN SE tho

16
New cards

TW arrives at your pharmacy with a new prescription for selegiline 5 mg po bid. Which of the following should be included in your directions to him when counseling about this new medication?

A

Take the drug on an empty stomach to increase absorption.

B

Take the second dose no later than mid-day.

C

Monitor for compulsive behaviors.

D

Take the drug as needed when "off" time occurs.

B

There is no stipulation that selegiline needs to be taken without food.

Answer b is correct. Because selegiline has an amphetamine metabolite, it can cause nighttime insomnia if taken too late in the day.

Answer c is incorrect. Monoamine oxidase (MAO) inhibitors do not commonly induce compulsive behaviors.

Answer d is incorrect. MAO inhibitors are indicated for chronic use to prolong the effects of carbidopa/levodopa. They are not intended for prn use.

17
New cards

PY is a patient with Parkinson disease who has a difficult time swallowing medications. His family states he sometimes chokes on his medications and when he drinks more than just a sip of liquid. Which medication used for the treatment of Parkinson disease is available in an oral formulation that might be a safer option for PY? Select all that apply.

A

Carbidopa/levodopa

B

Pramipexole

C

Selegiline

D

Trihexyphenidyl

A, C

.Carbidopa/levodopa is available as an orally disintegrating tablet that may be taken without liquid.

Answer b is incorrect. There is no orally disintegrating formulation of pramipexole available.

Answer c is correct. Selegiline is available as an orally disintegrating tablet that may be taken without liquid. Zelapar

Answer d is incorrect. There is no orally disintegrating formulation of trihexyphenidyl available.

18
New cards

JR has been experiencing nausea with an increase in his carbidopa/levodopa dose to 37.5/150 mg po tid. His physician tells him to take it with food, and you are asked to counsel JR about how best to do this. What meal is most appropriate when carbidopa/levodopa cannot be tolerated on an empty stomach?

A

Steak and potatoes

B

Salmon and brussels sprouts

C

Spaghetti with tomato sauce and garlic bread

D

An egg salad sandwich and a glass of milk

C

high in protein may result in diminished levels of dopamine in the brain due to competition for amino acid transporters.

19
New cards

Which of the following pertains to Neupro patches?

A

Store in the refrigerator.

B

Patches may be cut to obtain the appropriate dose.

C

Apply the patch to the same site every day.

D

Protect the patches from light.

D

Neupro does not require refrigeration.

Answer b is incorrect. Neupro patches should not be cut.

Answer c is incorrect. The application site should be rotated to minimize the possibility of irritation.

Answer d is correct. Neupro patches should be protected from light until ready for use.

20
New cards

AB is a 57-year-old woman who has just been diagnosed by a movement disorder specialist in your clinic as having Parkinson disease. Her diagnosis was delayed as she lives in a rural area, and there are no neurologists near her home. She presents with moderate bradykinesia, and only mild tremor and rigidity on her right side. She is not currently taking any other medications. Which of the following are appropriate to be considered as monotherapy for AB? Select all that apply.

A

Carbidopa/levodopa

B

Benztropine

C

Pramipexole

D

Rasagiline

A, C, D

.Carbidopa/levodopa replaces dopamine, therefore appropriate to treat all of the symptoms of Parkinson disease exhibited by AB.

Answer b is incorrect.Benztropine is an anticholinergic medication that is appropriate primarily for patients who have a predominant tremor. It might treat AB's rigidity but is unlikely to be particularly efficacious for bradykinesia. In addition, use is possibly linked to an increased risk of dementia in the future.

Answer c is correct. While not as potent as carbidopa/levodopa, the dopamine agonist pramipexole will treat all of AB's Parkinson disease symptoms.

Answer d is correct. Rasagiline can be used as monotherapy early in Parkinson disease treatment as long as the patient has enough endogenous dopamine for the drug, a monoamine oxidase (MAO) inhibitor, to act upon (as patients in the early stages of the disease typically do).

21
New cards

Your patient TL was just prescribed Zelapar, and you are counseling him on use. What do you tell him with regard to instructions for storage and handling? Select all that apply.

A

Open the blister packs and store the tablets in a light-tight container for travel convenience.

B

Discard unused tablets after 3 months of opening the pouch containing the blister packs.

C

Place no more than 1 week's worth of tablets in a pill organizer as exposure to air renders the tables less potent after one week outside the blister pack.

D

Use the tablet immediately after removing from the blister pack.

B, D

Tablets should remain in the blister pack until ready for use.

Answer B is correct. The manufacturer recommends that all tablets within the pouch be used within 3 months after opening to ensure potency.

Answer C is incorrect. Tablets should remain in the blister pack until ready for use.

Answer D is correct. Tablets should remain in the blister pack until ready for use.

22
New cards

TS lives in a rural community where there is no neurology practice. For the past several years, he has been experiencing tremors, rigidity, and bradykinesia that began on his left side, but has since migrated and become bilateral. He is diagnosed with Parkinson disease and his motor symptoms are graded as moderate (tremor and bradykinesia), and moderate-severe (rigidity). What is the most appropriate order for the initiation and progression of treatment for his Parkinson disease?

A

Benztropine, rasagiline, carbidopa/levodopa

B

Pramipexole, entacapone, carbidopa/levodopa

C

Ropinirole, levodopa/carbidopa, tolcapone

D

Carbidopa/levodopa, rotigotine, rasagiline

D

For patients with more prominent symptoms, carbidopa/levodopa is the preferred agent to initiate therapy. The addition of a dopamine agonist is appropriate as second-line therapy. The addition of an monoamine oxidase (MAO)-B inhibitor will help prolong the effects of dopamine by minimizing it's metabolism by MAO.

Answer a is incorrect. An anticholinergic agent is used primarily for tremor, and since its effect on symptoms is mild, it is not indicated for someone with advanced disease. For patients with more prominent symptoms, carbidopa/levodopa is the preferred agent to initiate therapy.

Answer b is incorrect. While the choice of a dopamine agonist as initial therapy is not inappropriate, for patients with more prominent symptoms, carbidopa/levodopa is the preferred agent to initiate therapy. Entacapone cannot be utilized until carbidopa/levodopa is part of the medication regimen.

23
New cards

What is the role of entacapone in the treatment of Parkinson disease?

A

It inhibits catechol-o-methyltransferase (COMT) in the brain.

B

It inhibits COMT in the periphery.

C

It inhibits monoamine oxidase (MAO) in the brain.

D

It inhibits MAO in the periphery.

B

. Entacapone works peripherally only, while tolcapone works in both the brain and the periphery.

24
New cards

TS has a long-standing history of resistant clinical depression, and is currently being treated with phenelzine 30 mg po bid. Which Parkinson disease medications can TS not use while on this medication? Select all that apply.

A

Istradefylline

B

Safinamide

C

Rasagiline

D

Rotigotine

B, C

25
New cards

HO's neurologist added entacapone to his carbidopa/levodopa regimen today. He currently takes carbidopa/levodopa 50/200 mg po qid. Which counseling points are appropriate for HO? Select all that apply.

A

Entacapone must be taken at the same time as the carbidopa/levodopa.

B

Entacapone may turn urine orange.

C

Entacapone requires a patient to schedule routine liver function tests.

D

Entacapone can cause narcoleptic-like sleep attacks.

A, B

Unlike tolcapone which may be dosed independently of carbidopa/levodopa due to its ability to cross the blood-brain barrier, entacapone works in the periphery only. As such, it must be dosed at the same time as carbidopa/levodopa in order to exert its effects.

Answer b is correct. Patients should be told that entacapone may turn body fluids orange.

Answer c is incorrect. Unlike tolcapone, entacapone is not known to be hepatotoxic.

Answer d is incorrect. While users or dopamine agonists have described sleep attacks akin to narcolepsy, this side effect has not been associated with the catechol-o-methyltransferase (COMT) inhibitors.